multiple endocrine neoplasia type 1
Information
- Disease name
- multiple endocrine neoplasia type 1
- Disease ID
- DOID:10017
- Description
- "A multiple endocrine neoplasia that has_material_basis_in a mutation in the MEN1 tumor suppressor gene and is characterized by over active endocrine glands frequently involving tumors of the parathyroid glands, the pituitary gland, and the pancreas." [url:http\://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia_type_1, url:http\://ghr.nlm.nih.gov/condition/multiple-endocrine-neoplasia, url:http\://www.nlm.nih.gov/medlineplus/ency/article/000398.htm, url:https\://www.ncbi.nlm.nih.gov/pubmed/25509899]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03950609 | Active, not recruiting | Phase 2 | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | July 30, 2019 | June 30, 2025 |
| NCT00454363 | Completed | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | March 2007 | December 2014 |
| NCT02101918 | Completed | Phase 2 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | June 18, 2014 | January 31, 2018 |
| NCT05554744 | Recruiting | N/A | EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | June 18, 2015 | December 2025 |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT03050268 | Recruiting | Familial Investigations of Childhood Cancer Predisposition | April 6, 2017 | March 31, 2037 | |
| NCT05037461 | Recruiting | N/A | Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients | May 1, 2022 | December 1, 2026 |
| NCT03001349 | Terminated | Early Phase 1 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | May 16, 2017 | February 5, 2021 |
| NCT02831179 | Withdrawn | Phase 1 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | December 2017 | February 2020 |
- Cross Reference ID (Disease Ontology)
- ICD10CM:E31.21
- Exact Synonym (Disease Ontology)
- MEN type I
- Exact Synonym (Disease Ontology)
- Wermer syndrome
- Exact Synonym (Disease Ontology)
- Wermer's syndrome
- Disase is a (Disease Ontology)
- DOID:3125
- Cross Reference ID (Disease Ontology)
- GARD:3829
- Cross Reference ID (Disease Ontology)
- ICD9CM:258.01
- Cross Reference ID (Disease Ontology)
- MESH:D018761
- Cross Reference ID (Disease Ontology)
- MIM:131100
- Cross Reference ID (Disease Ontology)
- NCI:C3225
- Cross Reference ID (Disease Ontology)
- ORDO:652
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:30664006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0025267
- OrphaNumber from OrphaNet (Orphanet)
- 652
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018761